chartexchange

Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone

GlobeNewswire Inc. | Nov 16, 2026 7:37 AM EST

Vancouver, Canada, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the successful completion of patient enrollment for Part C of its ongoing Phase I/IIa clinical trial evaluating CMND-100.

Read original article